mTOR (mechanistic target of rapamycin complex 1), via FKBP-12

Class

mTOR inhibitor; albumin-bound nanoparticle formulation of sirolimus (CSPC ZhongQi's HB1901) — same active moiety as, but a distinct product from, the US-approved nab-sirolimus Fyarro

Pathway

PI3K/AKT/mTOR signaling pathway; sirolimus binds FKBP-12 to form a complex that inhibits mTORC1, blocking downstream cell growth, survival and proliferation signaling

The mechanistic target of rapamycin (mTOR) is a kinase that sits within the PI3K/AKT/mTOR signaling pathway, a central hub coordinating cell growth, protein synthesis, metabolism and proliferation in response to nutrients, energy status and growth factor signals. Sirolimus and related agents do not inhibit mTOR directly; they first bind an intracellular protein called FKBP-12, and this drug-protein complex then engages mTOR complex 1 (mTORC1), dampening its output. Because many cancers and certain benign but destructive tumors arise from mutations that hyperactivate this pathway, blocking mTORC1 can slow abnormal cell growth and division. The same pathway also governs immune cell proliferation, which is why mTOR inhibition has a long history in transplant immunosuppression as well as oncology. A distinguishing feature of this particular product is its albumin-bound nanoparticle formulation, an approach used to deliver a poorly water-soluble small molecule without relying on harsh chemical solvents, potentially improving how the drug is distributed and taken up by tissue. This formulation strategy is a delivery-engineering choice layered atop a well-established biological mechanism, rather than a new mechanism itself.